CHU Bordeaux
Bordeaux, France
NCT Number: NCT04569175
This study includes 30 patients with Meniere's disease confirmed with AAO-HNS criteria.
The aim of this study is to compare the new optimized 3D FLAIR sequence developed at our site with a standard 3D FLAIR sequence performed 4h after a single intravenous dose of macrocyclic gadolinium-based contrast agents for the detection of endolymphatic hydrops.
The patients will be explored with the new 3D FLAIR optimized sequence before injection (method to validate) and again 4 hours after contrast media administration with the same sequence 3D FLAIR
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bordeaux, France
Meniere's disease (MD) is a pathology of the inner ear defined by episodes of spontaneous vertigo usually accompanied by tinnitus, pressure within the ear and fluctuating sensorineural hearing loss.
Endolymphatic hydrops (EH) is the main pathophysiological substratum of Meniere's disease. Temporal bone MRI has long been used performed to exclude other pathologies mimicking MD, such as vestibular schwannoma or endolymphatic sac tumor.
Currently, delayed 3D-FLAIR sequence is the imaging technique of choice for the diagnosis of endolymphatic hydrops. The endolymphatic space could be assessed on MRI with 3D-FLAIR sequences delayed acquisition after the intravenous administration of gadolinium.
The saccule appears to be the most involved structure in MD. The reproducibility of the hydrops protocols with various MRI scan manufacturers is debatable.
Because endo and peri lymphatic spaces have different biochemical compositions, a new FLAIR 3D sequence on healthy volunteers can be tuned in order to separate endo and peri lymphatic spaces. The hypothesis of the study is that this new method could detect saccular hydrops with the same performances as the standard FLAIR that is done after gadolinium injection.
This study will prospectively include 30 patients with MD confirmed with AAO-HNS criteria . All patients will sign an informed consent. They will be explored with the new 3D FLAIR optimized sequence without injection (method to validate). Then, they will be injected, and they will be explored again 4 hours after contrast product administration with the same sequence (the reference method),to take advantage of the intravenous injection of gadolinium that will be performed in the care. The optimized non enhanced 3D FLAIR sequence will be compared with the reference method and with the same sequence four hours after gadolinium injection.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Non inclusion criteria:
Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
Time frame: 1 hour before baseline (usual care MRI)
the non-inferiority of the non-enhanced Flair sequence compared to the reference technique by indirect comparison with the reference method (Kappa coefficient > or equal to 0.81).
Time frame: 1 hour before baseline, baseline, 4 hours after baseline
inter-observer correlation coefficient (weighted Kappa).
Time frame: 1 hour before baseline, baseline, 4 hours after baseline
Patient's clinical categorization according to the diagnostic criteria for Meniere's disease formulated by the Classification Committee of the Barany Society in 2015 : definite Meniere's disease and probable Meniere's disease.
Time frame: 1 hour before baseline, baseline, 4 hours after baseline
degree of endolymphatic hydrops: grade I/II/III
Time frame: 1 hour before baseline, baseline, 4 hours after baseline
Volume of endolymphatic hydrops: quantification (mm3)
Time frame: 1 hour before baseline, baseline, 4 hours after baseline
peak width in multifrequency tympanometry: average +/- standard deviation
Time frame: 1 hour before baseline, baseline, 4 hours after baseline
Resonant frequency: 0 to 2000 Hz
University Hospital, Bordeaux
Other
Acronym: NELI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04677972
Dizziness, Ear Diseases
Little Rock, Arkansas, United States
View Trial DetailsNCT05960786
BPPV, Benign Paroxysmal Positional Vertigo
Washington D.C., District of Columbia, United States
View Trial DetailsNCT04766853
Ear Diseases, Endolymphatic Hydrops
Seoul, South Korea
View Trial DetailsNCT06544590
Ear Diseases, Endolymphatic Hydrops
Beijing, Beijing Municipality, China
View Trial Details